LMK-235 cas 1418033-25-6

LMK-235 is a selective histone deacetylase (HDAC) 4 and HDAC5 inhibitor. LMK-235 demonstrates activity against chemoresistant cancer cell lines in an MTT assay for cytotoxicity using human ovarian cancer cell lines A2780 and cisplatin resistant A2780CisR (IC50 = 0.49 and 0.32 μ M respectively).

HDAC Inhibitors Related Prodcuts:

Mocetinostat; Dacinostat; Belinostat; Tacedinaline; RoMidepsin; Givinostat; Vorinostat; Tubastatin A HCl; Entinostat; Panobinostat; Trichostatin A; Pracinostat; AR-42; Ricolinostat; WT161; ACY-738; Tasquinimod; Domatinostat; BRD3308

[1]. Marek L, et al. Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells. J Med Chem. 2013 Jan 24;56(2):427-36.

[2]. Li A, et al. HDAC5, a potential therapeutic target and prognostic biomarker, promotes proliferation, invasion and migration in human breast cancer. Oncotarget. 2016 Jun 21;7(25):37966-37978.